X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect the safety and efficacy of immune checkpoint inhibitor therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Medical Center Utrecht
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2022
Details:
ARZC-001 is a novel, oral, gut-restricted potent small molecule inhibitor that is designed to neutralize a specific secreted factor of microbial-driven dysregulation and inflammation in the intestine.
Lead Product(s): ARZC-001
Therapeutic Area: Gastroenterology Product Name: ARZC-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease (“IBD”), which is anticipated to enter the clinic in 2022, as well as to explore additional disease targets.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Hatteras Venture
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
